Abstract: Herein we report aCRISPR-Cas9-mediated loss-offunction kinase screen for cancer cell deformability and invasive potential in ah igh-throughput microfluidic chip.I n this microfluidic cell separation platform, flexible cells with high deformability and metastatic propensity flowed out, while stiff cells remained trapped. Through deep sequencing,w e found that loss of certain kinases resulted in cells becoming more deformable and invasive.H igh-ranking candidates identified included well-reported tumor suppressor kinases, such as chk2, IKK-a,p 38 MAPKs,a nd DAPK2. Ah ighranking candidate STK4 was chosen for functional validation and identified to play an important role in the regulation of cell deformability and tumor suppression. Collectively,w eh ave demonstrated that CRISPR-based on-chip mechanical screening is ap otentially powerful strategy to facilitate systematic genetic analyses.
Systematic loss-of-function genetic screening is an essential approach to identify genes and pathways involved in many biological processes and diseases.
[1] TheC RISPR (clustered regularly interspaced short palindromic repeats) Cas9 system represents an efficient tool for such screening and has been successfully utilized to identify genes that regulate cell survival, confer drug resistance,a nd/or drive tumor metastasis. [2] TheCRISPR approach provides complete deletion of the target and yields cells with representative phenotypes. [3] A plethora of screening methods can then be used to sort such phenotypes and search for potential biomarkers. [4] CRISPRbased genetic screening has been achieved in both human cells and mouse models,which demonstrates that Cas9-based screening is ar obust method to systematically assay gene functions. [2] Thecurrent cancer biomarker screening methods mainly rely on in vitro or in vivo cell proliferation and metastasis assays on the knockout cell phenotypes. [2, 5] Such assays are often hindered by efficiency as well as extended time and effort, because of limited throughput and prolonged characterization and selection of cells.Integrated microfluidic chips are uniquely advantageous in improving the efficiency of CRISPR-based screening and may potentially recapitulate essential cellular activities spatially and temporally. [6] Such microfluidic chips have also been well-designed with microand nanostructures to rapidly distinguish cell morphology and dynamics. [7] When applied to cell phenotype selection for biomarker development, these highly integrated microchips have great promise to link the cell phenotypes with their gene deletions,i nafast, efficient, and specific manner. Here we combined the CRISPR/Cas9 screen with cell-mechanicsbased on-chip sorting to identify tumor-suppressor kinases. Compared with traditional screening for cellular activities, cell-mechanics-based sorting in amicrofluidic chip is alabelfree,h igh-throughput, cost-effective,a nd time-saving approach, which will likely accelerate the discovery of genes and pathways underlying key cellular processes.T he presented method is the first CRISPR screening example developed in the field of microfluidics biotechnology.
Celldeformabilityisapromisinglabel-free biomarker that indicates changes in cytoskeletal or nuclear organization. Researcho nt he mechanical phenotypingo fc ancer cellsh as consistently revealed that high deformabilityisassociated with increased tumor-initiatingcapacityand metastaticpotential, [7a, 8] which suggests that genetic screeningb ased on cell deformabilitym ay allowf or thed iscovery of newc ancer biomarkers. Theuse of amicrofluidics high-throughputassay to performthe CRISPR-based screeningi snew int he field and may provide higher efficiencyand lower cost when studyingg enefunctions. Thereare notablemicrofluidiccell deformability assays that are suitable forsuch screening. Thedeformability assays have been reportedf or the enrichment and isolationofcancerc ells from blood and cytometryb ased on biophysics.
[7a, 8b,9] We herein continueo ur biophysical cytometry studiesa nd provide af irst example of CRISPR-based screeninginamicrofluidics system. Amicrofluidic cell deformabilityassay enablesCRISPR-based screeningw ithh igh efficiency,w hich canl inkt he mechanical phenotypes of the cell withg ened eletions in af ast, efficient, and specific manner.T he mechanics-basedb iomarker-screeningstrategy will facilitate research intocancercellmetastasisas well as clinicalt herapy applications,e specially in types of cells forw hich biomarkers have not yet been discovered. Our microfluidic methodisabletohandle theseparationofmillions of cellso nt he basiso ft heird eformabilityi nl esst han 30 minutes and provide unique opportunities for thescreening of genef unction.
In this study,wecombined the CRISPR-Cas9 screen with ac ell-deformability-based on-chip sorting to identify tumorsuppressor kinases.Our research group has designed aunique cell purification system for sorting highly deformable cells in ah igh-throughput method.
[7a] Here we have optimized the device according to the cell size.T his microfluidic device allows flexible cells with high deformability and metastatic propensity to pass through the microbarriers and exit the separation chip under hydrodynamic forces,whereas stiff cells remain trapped. This unique purification system based on the mechanical properties of cells is combined with CRISPRCas9 knockout technologies to enrich highly deformable cell subpopulations.T hrough high-throughput sequencing analysis,w es uccessfully identified potential kinases whose losses are involved in cell deformability and invasion regulation. Our highest ranking candidates cover well-reported tumorsuppressor kinases such as chk2 (checkpoint kinase 2), IKKa (IkappaB kinase alpha), p38 MAPKs (p38 mitogenactivated protein kinases), and DAPK2 (death-associated protein kinase 2), as well as novel hits MAST1 (microtubule associated serine/threonine kinase 1) and STK4 (serine/ threonine kinase 4). Functional validation of cellular and molecular phenotypes demonstrated STK4 to be ap otential novel tumor suppressor in breast cancer. Compared with traditional screening for cellular activities,sorting on the basis of cell mechanics in am icrofluidic chip is al abel-free,h ighthroughput, cost-effective,a nd time-saving approach, which will likely accelerate the discovery of genes and pathways underlying key cellular processes.
We first designed and validated the cell-separation capability of the microfluidic deformability chip (named the mechanical separation chip (MS-Chip)). TheM S-Chip utilizes artificial microbarriers to separate flexible cells from stiff ones by hydrodynamic forces,and the separating structure is composed of two million rectangular microposts 30 mmi n height arrayed with gap distances decreasing from 15 mmt o 6 mm( Figure 1A and Figure S1 ). As aproof of concept study, a1 :1 mixture of human breast cancer MDA-MB-231 cells treated with either ad imethylsulfoxide (DMSO) control or cytoskeleton-inhibiting drug Cytochalasin Dw ere applied to the MS-Chip to validate the separation efficiency.T reatment with cytochalasin Dinhibits actin polymerization, reduces Factin bundling,and enhances flexibility, [10] as demonstrated by on-chip staining of trapped cells ( Figure S2A Figure 1B ). Statistical analysis of onchip transport distance versus cell diameter reveals distinct separation efficiencies for the two treatments ( Figure S2C ). Thea verage transport distances of cells treated with Cytochalasin Dwere about 1.7-fold greater than those of DMSOtreated cells.W hen ah igher flow rate of 75 mLmin À1 was applied, acomparison of the cell populations at the inlet and outlet ( Figure 1C )s howed that cells treated with Cytochalasin Da ccumulated at the outlet, and accounted for 88 %o f the cell population versus 50 %o ft he inlet population ( Figure 1D ). It should be noted that cell heterogeneity, which includes characteristics such as cell size and cell-cycle phases,a ffects the separation efficiency.N evertheless,t he cells treated with Cytochalasin Dwere transported farther in the chip,a nd because no clear correlation between cell diameter and transport distance has been established (Figure S2C ), these data indicate that changes in the cytoskeleton distribution induced by Cytochalasin Da re responsible for the separation in the chip of cells treated with Cytochalasin D from those treated with DMSO.
Since the MS-Chip enriches flexible cells at the end of the micropost array and the mechanical property of ac ell is correlated with its metastatic potential, [7a] we explored the possibility of applying such am echanical cell-sorting approach with the CRISPR-Cas9 knockout (KO) technology. As an initial test, as ingle-guide RNA( sgRNA) library targeting 507 kinase genes was screened for potential genes involved in the regulation of cell deformability (Figure 2A) . First, we generated aderivative of the MDA-MB-231 cell line that stably expresses FLAG-Cas9 under ad oxycycline-inducible promoter ( Figure 2B ). We transduced the Cas9-expressing cell line with aC RISPR kinase-KOl entivirus pool at aratio of more than 500 cells per lentiviral CRISPR construct. After culturing the cells in vitro for 1week, the transduced cells were loaded onto an MS-Chip for sorting.N ontransduced cells expressing FLAG-Cas9 were also loaded as ac ontrol. Thes tatistical data demonstrated that the CRISPR kinase-KOc ells were more heterogeneous when characterized by the on-chip transport distance,but there was no apparent change in the diameter of the cells ( Figure 2C ). As expected, asmall portion of the transduced cells (ca. 15 %) traveled further in the chip,a nd these cells with higher deformability were allowed to flow out of the MS-Chip.Based on our earlier investigation, we find that the collection of 15 %o ft he cells at the outlet of the devices provides as ignificant difference in their deformability over the cells retained in the devices.W eanalyzed the cell size of CRISPR kinase-KOc ells before and after separation by the MS-chip ( Figure S3 ). There is no large difference in the average cell size before and after separation, thus suggesting that differences in cell deformability are responsible for the separation of the cells in the chip.A lthough the shear stress will affect gene expression, it wont be able to change cell functions in less than 30 minutes.O ur screening strategy is based on cell function versus loss of aspecific gene applied earlier with the CRISPR-based knockout. Thec hange in gene expression during the assay will not matter.T he cell viability was also measured for CRISPR kinase-KOc ells before and after separation ( Figure S4 ). Ther esults showed that on-chip processing of this cell separation had little affect on the cell viability.T hen we sequenced the sgRNAb arcodes of the sorted flexible cells (from the output), as well as the entire initial pool of cells (from the input). We did the cumulative distribution analysis of sgRNAc ounts and found the distribution was similar in two independent experiments (Figure S5) . High correlations were achieved among replicates ( Figure S6 ). Thed istribution of the fraction of detected sgRNAwas analyzed for all the 507 kinase genes ( Figure S7 ). In most of the genes,8/9 pairs of the sgRNAcan be detected, which suggested the reliability of our sgRNAp ool as well as the consistency between same-gene-targeting sgRNAs.T o identify gene hits,weevaluated the change for each sgRNAin the output and the input cell populations.T op sgRNAh its were identified by using the cutoff of log 2 (fold change) > 7 and a p value < 0.001 ( Figure 2D ). We identified 38 potential candidate genes with at least two independent sgRNAs among the top hits,w hose function may be involved in the regulation of cell deformability and invasion (Table S1 ). The fraction of the detected sgRNAoftop-ranked genes was also analyzed ( Figure S8 ). According to our hypothesis,the loss of tumor-suppressor genes would drive cells to become more flexible and invasive.A sexpected, we identified 15 known kinase tumor suppressors,i ncluding chk2, IKK-a, p38 MAPKs,a nd DAPK2 (Table S1 ), thus confirming that our screening approach is effective.W ehypothesize that the rest of the list would be new potential tumor suppressors.
With increased cutoff criteria, two novel genes, MAST1 and STK4,were selected for further validation. Both MAST1 and STK4 showed three independent sgRNAs in the top hits. We generated two isogenic MDA-MB-231 cell lines with sgRNAs against MAST1 and STK4,a nd, consistent with our screening data, the MAST1 and STK4 KO cells were transported longer distances in MS-Chips than the wild-type (WT) cells at al ower flow rate of 25 mLmin À1 ( Figure 3A and Figure S9 ). After on-chip-separation at ah igher flow rate of 75 mLmin À1 ,the percentages of MAST1 and STK4 KO cells in the output increased about 1.6-fold and 2.4-fold, respectively ( Figure 3B-E) . Thecells solely expressing FLAG-Cas9 were used as the control to rule out the effect of Cas9 expression on cell-transport ability in the chip.T hese data confirmed the reliability of the cell-deformability-based kinase screening.
Thec ytoskeletals tructurep lays am ajor role in cell deformabilitya nd it is usuallya nalyzedb ym easuring the expression of F-actin, cytokeratin18, andv imentin. [11] We explored howS TK4r egulates thec elld eformability by analyzingt he expression andd istributiono ft hese three molecules. STK4 is theh uman orthologue of Drosophila Hippo, thec entral constituento fahighly conservedp athway controllingc ellg rowtha nd apoptosis. [12] STK4 deficiency is anovel humanprimary immunodeficiency syndrome. [13] STK4 hasb eenr eportedt os uppresst he developmento fh epatocellularc arcinoma throughi nactivationo ft he Hippom ediator YAP1. [14] In hematologicalc ancers,t he inhibition of STK4 geneticallytriggersY AP1-mediated apoptosis. [15] We generated threed ifferent STK4 KO breast cancer cell lines, analyzed them by theM S-Chip,a nd foundt hata ll threeo ft hemw ere presenta th igherp ercentagesi nt he output compared to WT cells( Figure 4A ). In addition,a ccording to confocal imaging, STK4 appeared to colocalize with F-actin(Figure4B);wedid notobserve anyapparentcolocalizationofSTK4withCK18or vimentin (FigureS10A,B) .F urthermore,t he bundling of Factinwas reducedinthe STK4-depleted cells( Figure 4C) ; the distributionso fCK18 andv imentinw erea lsoa ffected ( Figure4Ca nd Figure S10C ). However, we didn ot detect apparent changesi nt he proteinl evel of F-actin, CK18,o r vimentin (Figure4D),thereby suggesting that theroleofSTK4 in cell deformabilitym ay be regulatedt hrough remodeling of thec ytoskeleton. To conclude,t he altered distribution and assembly rather than thea mounto fc ytoskeletals tructure markersm ay be responsiblef or thei ncreased cell deformabilityinSTK4 KO cells.
We next explored the function loss of STK4 in tumorigenicity by using an ontumor MCF-10A breast cell line. Consistent with our previous results,STK4 colocalized with Factin in the MCF-10A cells ( Figure 5A ). Depletion of STK4 yielded an invasive phenotype of the MCF-10A cells,w hich has been associated with the up-regulation of multiple genes involved in the motility and metastasis of cancer cells (Figure 5B-D) . Mammosphere formation assays revealed as ignificant increase in the size and numbers of mammospheres in the STK4 KO MCF-10A cells ( Figure 5E ). Additionally,t he ratio of the CD44 high /CD24 low stem-cell-like subpopulation significantly increased from 1.9 %i nM CF- 10A control cells to 18 %i nSTK4 KO cells ( Figure 5F ). All these results demonstrate that STK4 deficiencyenhances cell invasiveness in MCF-10A cells.T he specific role of STK4 in the regulation of cell deformability and tumor suppression is thus confirmed in breast cancer through this genome-wide screening,w hich echoes the earlier finding in other cancer types. [12a,c, 14] Interestingly,the correlation between STK4 gene expression in breast tumor biopsies and patient survival was analyzed by mining apublicly available database established by Clynes,B ertucci et al. [16] (R2 Genomics Analysis and Visualization Platform (http://r2.amc.nl);F igure S11). Low expression of STK4 in breast cancer samples predicted apoor overall patient survival rate,thus indicating that STK4 may be anovel suppressor of breast cancer tumors.
Our findings show that combining microfluidic sorting systems based on the mechanical properties of cells with CRISPR-Cas9 technologies is an ovel genetic screening strategy that facilitates the rapid identification of genes that play roles in mechanical phenotypes,a sw ell as in physiological and pathological processes.Our investigation provides the first lab-on-chip example to rapidly screen gene function based on the CRISPR knockout system. There are other wellestablished on-chip cell function assays such as cell adhesion, cell migration, proteomics,a nd viability assays.T his study provides an example and all such assays can be integrated for the screening of gene function with proper device designs. Our study opens anew avenue for the large-scale integration of the on-chip study of cell function and search for such potential biomarkers.
